Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Blood (2023) 142 (Supplement 1): 6741.

https://doi.org/10.1182/blood-2023-185699

Published: 2023

Journal Articles

Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype

Alexandre Willaume, Mourtaza Karimdjee, Sandy Amorim, Benjamin Carpentier, Benedicte Hivert, Emmanuelle Bourgeois-Petit, Pierre Gosset, Alban Bailliez, Laurent Pascal

Blood (2022) 140 (Supplement 1): 3835–3836.

https://doi.org/10.1182/blood-2022-159375

Published: 2022

Journal Articles

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Blood (2022) 140 (Supplement 1): 4423–4425.

https://doi.org/10.1182/blood-2022-168742

Published: 2022

Journal Articles

What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort

Blood (2022) 140 (Supplement 1): 4379–4381.

https://doi.org/10.1182/blood-2022-158484

Published: 2022

Journal Articles

Elevated Circulating Platelet-Derived Microparticles in Ph1 Negative Chronic Myeloproliferative Disorders.

Véronique Tintillier-Colin, Nathalie Cambier, MD, Emmanuelle Bourgeois-Petit, MD, Christian Rose, MD, Gérard Forzy, MD, Jean-Loup Demory, MD, Agnès Charpentier, MD

Blood (2009) 114 (22): 1906.

https://doi.org/10.1182/blood.V114.22.1906.1906

Published: 2009

Journal Articles

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study

Bertrand Godeau, Raphael Porcher, Olivier Fain, François Lefrère, Pierre Fenaux, Stéphane Cheze, Anne Vekhoff, Marie-Paule Chauveheid, Jerôme Stirnemann, Lionel Galicier, Emmanuelle Bourgeois, Stéphanie Haiat, Bruno Varet, Michel Leporrier, Thomas Papo, Mehdi Khellaf, Marc Michel, Philippe Bierling

Blood (2008) 112 (4): 999–1004.

https://doi.org/10.1182/blood-2008-01-131029

Published: 2008

Journal Articles

Rituximab Is an Alternative to Splenectomy in Adults with Chronic Immune Thrombocytopenic Purpura: Results of a Multicenter Prospective Phase 2 Study.

Bertrand Godeau, MD, Olivier Fain, MD, Raphael Porcher, MD, PhD, Francois Lefrere, MD, Pierre Fenaux, MD, PhD, Stephane Cheze, MD, Anne Vekhoff, MD, Marie-Paule Chauveheid, MD, Jerome Stirnemann, MD, Lionel Galicier, MD, Emmanuelle Bourgeois, MD, Stephanie Haiat, MD, Bruno Varet, MD, Michel Leporrier, MD, Thomas Papo, MD, Marc Michel, MD, Philippe Bierling, MD, PhD

Blood (2006) 108 (11): 478.

https://doi.org/10.1182/blood.V108.11.478.478

Published: 2006

Journal Articles

Quantification by Magnetic Resonance Imaging (MRI) and Consequences of Post-Transfusionnal Iron Overload in Long Bone Marrow Transplant Survivors.

Christian Rose, MD, Olivier Ernst, PD, Bernard Hecquet, MD, Pascale Renom, MD, Marie Pierre Noel, MD, Ibrahim Yakoub-Agha, MD, Emmanuelle Bourgeois, MD, Nathalie Cambier, MD, Francis Bauters, MD, Jean Pierre Jouet, MD

Blood (2005) 106 (11): 1112.

https://doi.org/10.1182/blood.V106.11.1112.1112

Published: 2005

Journal Articles

Reproducibility and Sensitivity in Assessing Liver Iron Content (LIC) in Highly Transfused Patients by Routine Magnetic Resonance Imaging(MRI).

Christian Rose, MD, Philippe Vandevenne, MD, Emmanuelle Bourgeois, MD, Nathalie Cambier, MD, Jean-Loup Demory, MD, Francis Bauters, MD, Olivier Ernst, MD, PhD

Blood (2004) 104 (11): 3208.

https://doi.org/10.1182/blood.V104.11.3208.3208

Published: 2004

NARROW

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort

Elevated Circulating Platelet-Derived Microparticles in Ph1 Negative Chronic Myeloproliferative Disorders.

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study

Rituximab Is an Alternative to Splenectomy in Adults with Chronic Immune Thrombocytopenic Purpura: Results of a Multicenter Prospective Phase 2 Study.

Quantification by Magnetic Resonance Imaging (MRI) and Consequences of Post-Transfusionnal Iron Overload in Long Bone Marrow Transplant Survivors.

Reproducibility and Sensitivity in Assessing Liver Iron Content (LIC) in Highly Transfused Patients by Routine Magnetic Resonance Imaging(MRI).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only